Background: Angiogenesis, the process whereby endothelial cells divide and migrate to form new blood capillaries, has been assessed in tumours by measuring microvessel density. High microvessel density is a significant adverse prognostic factor in breast cancer. The angiogenic factor, basic fibroblast growth factor (bFGF), has been associated with tumourigenesis and metastasis in several human cancers. There are few quantitative studies of bFGF expression in normal tissues compared to cancer.
Introduction
The growth of solid tumours is dependent upon the formation of new capillaries [1, 2] and subsequent tumour metastasis involves the interaction of neoplastic cells with this neovasculature [3] . Studies from this [4] and other laboratories [5] [6] [7] have shown that immunohistochemical quantification of microvessels is an independent prognostic factor.
Numerous angiogenic factors are known [8] and one of the most potent is bFGF, a member of the fibroblast growth factor family of proteins. The members of the FGF family are ligands for FGF receptors which have intrinsic tyrosine kinase activity. Basic FGF is synthesised by several cell types including fibroblasts, endothelial cells and macrophages. The protein lacks a secretory leader sequence and possible mechanisms for its release include export bound to extracellular matrix components [9] [10] [11] , externalisation in evaginated segments of plasma membrane [12] and release on either cell death or response to heat shock [13] . Fibroblast growth factors are involved in tumourigenesis [14] and metastasis [15] of mouse mammary tumours. Fibroblast growth factors confer tumourigenesis and autonomous cell growth when introduced via expression vectors into untransformed cells, such as Swiss 3T3 cells and hamster kidney-derived cells [16, 17] . When FGF-4 was transfected into the oestrogen responsive breast carcinoma cell line, MCF 7, the resultant transfectants formed tamoxifen resistant metastatic tumours when injected into ovariectomised nude mice [18] . Elevated levels of bFGF have been found in renal tumours [19] and in urine samples from patients with bladder cancer [20] . Furthermore, urinary levels of bFGF correlate with survival in breast cancer [21] .
The possible involvement of FGFs in tumourigenesis, angiogenesis and metastasis led us to examine the relationship between bFGF levels and microvessel counts, oestrogen receptor (ER), epidermal growth factor receptor (EGFR), tumour grade and survival in 149 primary breast carcinomas and in 21 non-neoplastic breast samples.
Patients and methods

Tumour samples
One hundred forty-nine breast tumours were collected as surgical resection specimens from patients with primary breast cancers. Fourteen samples of non-neoplastic tissue were removed from a site 5 cm or more away from the tumour and assessed histologically for the absence of tumour. Seven samples of normal breast tissue were obtained from mammoplasty reduction. Tumours were treated by simple mastectomy or lumpectomy with axillary node sampling. Patient and tumour details are summarised in Table 1 . Tumour grading was carried out according to the modified Bloom and Richardson method [22] . Patient follow-up was conducted every 3 months for the first 18 months and 6 monthly until 3 years, and yearly thereafter. Patients with confirmed recurrent disease were treated by endocrine therapy for soft tissue or skeletal disease or by chemotherapy for visceral disease or failed endocrine therapy. Patients with isolated soft tissue relapse also received radiotherapy. All node positive premenopausal patients and also node positive postmenopausal women with a tumour size greater than 3 cm or with grade 3 and ER negative tumours received six courses of chemotherapy (cyclophosphamide, metholrexate and 5-flurouracil). Tamoxifen was given to premenopausal patients with ER positive tumours and all postmenopausal women for five years. The median follow-up time was 41 months. Tissues were immediately brought to the laboratory on ice and snap frozen in liquid nitrogen and stored at -196 °C until assayed.
Tissue preparation
All procedures were carried out at 0-4 °C Tissues were pulverised in a mortar chilled in liquid nitrogen and homogenised in a ratio 1 :20 (weight/volume) in buffer (0 02 M Hepes, 0.00075 M EDTA, 0.001 M benzamidine, 0.001 M PMSF, 1 mg/ml ovomucoid, pH 7.4 at 20 °C) using three 10-s bursts of an Ultraurrax homogeniser. The homogenate was centrifuged at 3000 r.p.m. for 10 min. The supernatant was centrifuged at 37500 r.p.m. for 40 min. The pellet (crude membrane fraction) was resuspended in tris buffered saline, pH 7.4 at 20 °C and stored at -80 "C until assayed for epidermal growth factor receptor (EGFR). The supernatant (cytosol) was made 0002 M with respect to dithiothreitol and stored at -80 C until assayed for oestrogen receptor (ER). Protein concentrations were determined using the method of Bradford [23] with bovine serum albumin as standard.
EGFR and ER assays
Oestrogen receptor content was determined using an ELISA technique (Abbott Laboratories, USA). Tumours were considered positive when cytosolic ER levels were greater than 10 fmol/mg cytosolic protein.
Receptor values were monitored by participation in the EORTC quality control scheme. EGFR was measured using ligand binding of 125 I-EGF to crude plasma membrane fractions [24] , Receptor values greater than 20 fmol/mg membrane protein were taken as positive.
Immunohistochemistry
Tissues were fixed in formalin and embedded in paraffin wax. Sections (4 jira) were digested with protease type XXIV (12.5 mg/100 ml phosphate buffered saline. (Sigma Chemical Company. Poole. UK.) for 20 min at 37 C prior to staining with anti-CD31 antibody [25] .
Paraffin embedded sections (4 urn) from breast cancer specimens were also incubated for one hour, at room temperature with 1 ug/ml rabbit anti human bFGFantibody (PeproTech Inc.. Rocky Hill. USA). Sections were rinsed three times in PBSA and incubated with a 1 :200 dilution of peroxidase conjugated goat anti rabbit antibody (Dako Ltd.. High Wycombe. UK) for 30 min at room temperature. The sections were washed three times in PBSA. Diaminobenzidinc was used as chromagen and incubated for 5 min at room temperature Sections were counterslained in haematoxylin, rinsed in water and mounted. A negative control omitting the primary antibody was used in each experiment.
Immunoblotting
Cytosols were electrophoresed on 12% reducing polyacrylamide gels [26] , Proteins were transferred onto immobilon-P membranes (Milhpore Corporation. Bedford. USA), blocked with 5% non fat milk powder and incubated overnight at 4 C with 2.5 ug/ml rabbit anti human bKGF antibody. Membranes were washed three times with PBSA and incubated one hour, at room temperature with a 1:1000 dilution of peroxidase conjugated goat anti rabbit antibody before washing three times with PBSA. Signals were visualised using ECL detection kit (Amersham International pic. Bucks., UK).
Assessment of micro\essel density
Measurements were carried out as described previously [25] . Vascular counts were determined without knowledge of patient outcome. The three most vascular areas where the highest number of discreet microvessels were chosen by two observers over a conference microscope. Microvessels were defined as any immunoreactive endothelial cells separate from adjacent microvessels and did not include vessels within the sclerotic body of the tumour. These maximal areas of neovascular-isation were visualised by scanning at low power (x40 and x 100). Vascular counts were then counted by both observers using a 25 point Chalkley eyepiece graticule at x250 magnification (at this magnification the graticule covered an area of 0.159 mm 2 ). The graticule was rotated in the eyepiece to where the maximum number of graticule dots overlaid immunohistochemically identified vessels or their lumens. Vessel counts for individual tumours were calculated using the mean of three graticule counts.
Basic FGF immunoassay
Concentrations of bFGF in breast cancer cytosols were quantified using a Quantikine' human bFGF immunoassay (R&D Systems. Minneapolis. USA). Cytosols. prepared as described above, were diluted with buffer (as above) and incubated, in triplicate, overnight at 4 °C on microtitre plates coated with a murine monoclonal antibody against human bFGF Unbound proteins were washed off and an enzyme-linked polyclonal antibody specific for bFGF was added to "sandwich" the bFGF immobilised during the first incubation. A substrate solution for horseradish peroxidase was added and the colour allowed to develop for 20 min at room temperature before the reaction was terminated by the addition of 2M sulphuric acid. The optical density of the colour was read at 450 and 405 nm, the latter value being subtracted from the former. A standard curve, consisting of known amounts of bFGF. was carried through the above procedure and the concentrations of bFGF in the cytosols was determined from this curve. Concentrations of bFGF were expressed as pg/mg cytosol protein
Prior to analysis of breast cytosols the assay was further validated. Firstly, using a variety of buffer diluents, including that used to homogenise tissues, there was shown to be no effect on the bFGF standard curve. Secondly, the concentration of total protein in each cytosol did not effect bFGF results. Lastly, the assay was linear over a 10-fold range of cytosol volumes
The assay is sensitive to lpg bFGF/ml sample and is specific to human and bovine bFGFs.
Statistics
Spearman rank correlation coefficients were used to examine relationships between continuous patient and tumour characteristics and bFGF as a continuous variable. To normalise bFGF log transformation was performed. The two-sample (-test was then used to compare the difference between mean log bFGF in categorical variables Kaplan-Meier survival curves were plotted from diagnosis to first relapse and death, categorised according to bFGF value; logrank statistics were calculated to compare these survival curves between high and low bFGF groups Multivanate Cox analysis was used to determine the effect of log bFGF and other prognostic variables on RFS and OS. Also bFGF split by the median into high and low groups was studied. Statistical analysis was carried out with the BMDP package (BMDP, Los Angeles, USA) and the Stata package (Stata Corporation, College Station, TX. USA).
Results
Patient characteristics
The patient and tumour variables of a consecutive series of patients are shown in Table 1 .
Basic FGF concentrations
Basic FGF was detected in all 149 tumour cytosols and 21 nontumour cytosols analysed in this study. A log transform was performed to reduce the skewness of the bFGF distribution. In the tumour cytosols the bFGF levels ranged between 27-12662, with a median of 441 pg/mg protein. In the 14 nontumour cytosols taken from a site away from the tumour the bFGF levels ranged between 32-509, with a median of 149 pg/mg protein. In seven reduction mammoplasty cytosols bFGF levels ranged between 15-63, with a median of 37 pg/mg protein. Basic FGF was significantly higher in tumour cytosols compared to nontumour cytosols (P < 0.0001, unpaired /-test, Table 2 ). Basic FGF was also significantly higher in nontumour cytosols taken from sites distant to the tumour compared to reduction mammoplasty cytosols (P -0.0003 unpaired /-test, Table 2 ). For subsequent comparisons bFGF and log bFGF were used as continuous variables and also compared as two groups split by the median.
Immunohistochemistry
Homogeneous endothelial staining with anti-CD31 was observed throughout the tissue section. Vessel counts ranged from 3.0-9.3, with a median of 6. There was no relationship between vessel counts and bFGF levels, either analysed as continuous variables or categorical groups split with cut point ^ 7.
Paraffin embedded sections from several tumours covering the range of bFGF expression as measured by immunoassay were stained with a rabbit anti human antibody. Representative sections are shown in Figure 1 . A high expressing bFGF tumour (12622 pg bFGF/ml cytosol) is shown in Figure la Figure lb and in all sections analysed by immunohistochemistry there was good agreement with the levels of bFGF as determined by immunoassay (results not shown). In both sections shown the bFGF was expressed abundantly in the stromal region. Tumour epithelium was negative. Tissue infiltrating lymphocytes were negative and there was immunostaining in the lumen of arterioles, probably as a result of endogenous peroxidase activity in erythrocytes (results not shown). 
Immunoblotting
To confirm that the above immunostaining was indeed bFGF, western blotting was carried out on a number of breast tumour and normal cytosols. A signal with molecular weight of approximately 18-20 kDa was visible in all tumour cytosols, however the intensity of this signal was considerably reduced, or absent, in the normal cytosols (results not shown).
Relationship of bFGF to other prognostic indicators
Using bFGF as a continuous variable versus other factors as continuous variables there was an association of borderline significance with oestrogen receptor (rho = 0.15, P = 0.06, Spearman correlation).
Using log bFGF as a continuous variable there was a significant inverse correlation with grade, comparing grade 3 to grade 1 and 2 combined (P -0.046, twosample /-test). Continuous log bFGF showed a direct relationship to ER ^ 10 fmol/mg protein {P = 0.01, twosample /-test) and an inverse relationship to size 5= 2 cm (P = 0.04, two-sample /-test). There was no association between bFGF, and patient age, EGFR, lymph node status and microvessel density as analysed by log bFGF or normal bFGF versus continuous or categorical variables.
Survival and bFGF
In a Cox univariate model, log bFGF was not a significant predictor for relapse free survival (RFS, P = 0.61) or overall survival (OS, P = 0.11). In a log-rank test, using bFGF stratified at the median (450 pg/mg protein), there was no significant difference between high and low bFGF in the life tables for RFS (P = 0.51) or OS (P = 0.39, Figures 2a and b, respectively) . Microvessel density, stratified at the cut point of ^ 7, showed a significant difference between high and low vessel counts for RFS (P = 0.02, Figure 3 ) but not for OS (P = 0.07, results not shown).
Multivariate analysis of survival
In a Cox multivariate model, each factor was taken as a continuous variable using log transforms for bFGF, ER and EGFR. Where grade was included (ductal cases) the dataset was 90 patients. Nodal status was significant for RFS and OS (P < 0.001 and P < 0.001, respectively). Tumour size was significant for RFS (P = 0.002), and EGFR was significant for OS (P -0.004, Table 3a ). In a model which included microvessel density it was significant for RFS (P -0.02, results not shown). Models excluding grade (126 cases) did not produce any different significant variables.
Using cut points to categorise the variables (Table 3b ) EGFR and nodes remained significant for OS.
In the Cox multivariate models, using bFGF (log transform) as a continuous variable, bFGF did not reach significance for OS or RFS, nor using bFGF as a categorical variable, stratified by the median (450 pg bFGF/mg protein).
Discussion
We have assayed the angiogenic factor bFGF in tumour cytosol and correlated expression of this growth factor with neovascularisation and patient survival. Levels of bFGF were significantly higher in tumour compared to nontumour cytosols irrespective of whether the sample was taken from a site adjacent to the tumour or from a mastectomy patient. Basic FGF levels were lower in mastectomy specimens compared to 'normal' samples at a distance from the tumour. Although the number of normal samples analysed was low the difference suggests that there are differences between completely normal tissues and normal tissues in a cancerous breast. This has been reported for other biochemical pathways eg aromatase activity [27] and genetic changes in breast cancer [28] . The finding of elevated bFGF levels in tumour cytosols is in agreement with results of other tumour types. Eguchi et al. [29] found that in six patients the transcripts for bFGF were consistently higher in renal cell carcinomas compared to their respective normal kidney samples [29] . Staining for bFGF peptide was also consistently higher in tumour compared to normal tissue. Basic FGF mRNA is expressed abundantly in gliomas, and meningiomas but not metastatic brain tumours and bFGF mRNA and bFGF peptide are localised in tumour cells by in situ hybridisation and immunohistochemistry [30] . This implies bFGF is produced in tumour cells.
Our results differ from Luqmani et al. [31] and Annandappa et al. [32] who found that using RTPCR or Northern blot analysis, bFGF mRNA was elevated in nontumour (benign) compared to tumour samples. This discrepancy can be partly explained by the fact that these studies compared tumours with benign cases whereas our study concerned tumours and normal adjacent samples. Secondly, the studies measuring mRNA levels used GAPDH to monitor for differences in RNA loading. Studies are now beginning to question the validity of utilising GAPDH as as internal control in RNA analysis due to the upregulation of GAPDH mRNA in prostatic tumour tissues [33] compared to normal tissues. Hypoxia, which is present in all tumours, upregulates expression of GAPDH [34] . GAPDH is also upregulated during proliferation [35, 36] and recent results from this laboratory [37] show that levels of GAPDH mRNA fluctuate six-fold when standardised against an external control in human breast carcinomas. This could explain the elevated levels of GAPDH in some tumours and the lower expression in normal tissues and would effectively underestimate bFGF mRNA levels in malignant hypoxic tissues. Furthermore, several isoforms of bFGF have been characterised [38] [39] [40] four of which target to the nucleus whilst one, the 18 kDa form, is cytoplasmic. It is feasible that our method of subcellular preparation fails to extract all five isoforms, therefore making it difficult to directly compare with other reported data where different extraction procedures were used.
O'Brien et al. [41] have shown that while the frequency and the amount of bFGF mRNA is markedly higher in normal compared to malignant (superficial and invasive) bladder samples there is no difference in expression of bFGF peptide between normal and invasive bladder. Furthermore, they argue that the bFGF in invasive tumours may have diffused into the tumour after enzymatic release by the tumour of bFGF from the basement membrane of normal tissue. In normal breast, Coope et al. [42] found that immunoreactive acidic FGF (aFGF) is present in the luminal epithelium and myoepithelial cells whereas in breast carcinoma aFGF is also present in the basement membrane and stroma associated with cancer cells. They suggest that stromal proteases in breast cancer release aFGF from storage sites in the normal epithelium thereby allowing aFGF availability to normal and malignant epithelial cells via an autocrine and or paracrine manner.
A recent report [43] presented evidence that there was no difference in the levels of bFGF between breast nonmalignant lesions and primary carcinomas and that breast cancer patients with low levels of bFGF had a significantly shorter disease free survival than patients with elevated bFGF. However they did not compare tumour with adjacent tissue in the same patients. They retrospectively chose a series of cut points that includes the median in our series. Thus the present study could be considered as one attempting to confirm the prognostic value. The higher bFGF protein in our study correlates with good prognostic features such as size and grade. This is compatible with higher bFGF RNA relating to good prognosis in other studies. In analysing our results we used the median value of 450 pmol/mg protein as cut point. There was no significant difference between high and low bFGF for either overall or relapse free survival. In addition, survival analysis using a multivariate Cox proportional hazard model showed that bFGF, as a continuous variable, did not reach significance for overall or relapse-free survival. The marked difference in the prognosis in the series of Colomer et al. [43] is not reflected in the other associations with bFGF, since they also found high bFGF associated with good prognostic features such as low stage, small size and progesterone receptor positivity. The differences may be related to a larger number of events in our study and the great heterogeneity of breast cancer.
Yiangou et al. [44] recently showed low bFGF mRNA in association with poor prognosis in breast cancer, and also that detection of bFGF by immunohistochemistry can be variable depending on fixation methods. They suggest that loss of staining of tumour bFGF may be related to greater lability possibly due to lack of binding to proteoglycans. This would be compatible with our results which show greater amounts of bFGF protein in tumour compared to normal breast tissues. Thus greater extractability may be characteristic of bFGF in breast cancer. Although mRNA for bFGF may be down regulated, our results suggest that there are greater amounts of extractable bFGF which may be available for stimulating growth, directly or indirectly.
There was no relationship between tumour microvessel counts and bFGF levels implying no direct involvement between bFGF and angiogenesis. A similar finding has been reported [45] when correlating vascular density with bFGF mRNA.
However, elevated bFGF levels, together with increased mortality risk, have been found in the serum of a minority of breast cancer patients [46] . Advanced cases have a high tumour burden compared with primary cases. The same authors [46] reported higher levels of urinary bFGF in breast cancer patients compared with urine from non cancer patients and that this was associated with poor survival. These results support our observation of high bFGF protein.
Our study does show significantly higher amounts of bFGF in breast carcinoma compared to normal breast samples. Localization of bFGF by Immunohistochemistry is currently difficult and shows variable results depending on staining and fixation methods. In all the sections we analysed bFGF was expressed abundantly in the stroma with the tumour epithelium being negative. In a series of breast cancers FGFR-1, one of three FGF receptors able to bind bFGF, was immunolocalised to the tumour epithelium with much weaker staining in the stroma [47] . This raises the possibility that stromal bFGF could interact in a paracrine manner with its receptor located in the tumour epithelium.
The results presented here show that malignant breast lesions contain a significantly higher level of bFGF compared to normal tissue, implying an involvement of bFGF in breast carcinogenesis. The lack of correlation between bFGF and microvessel numbers suggests that alone bFGF is not a key regulator of angiogenesis, but it may synergise with other factors, such as VEGF.
